|
Jan 16
|
Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
|
|
Jan 15
|
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
|
|
Jan 15
|
EVAX Adjusts Share Ratio
|
|
Jan 14
|
Evaxion announces completion of ADS ratio change
|
|
Dec 30
|
Evaxion announces plan to implement ADS ratio change
|
|
Oct 3
|
AI from EVAX Improves Trial Results
|
|
Oct 3
|
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
|
|
Sep 26
|
Evaxion significantly expands vaccine development collaboration with MSD
|
|
Sep 26
|
EVAX Process Continues to Garner Interest and Investment
|
|
Aug 29
|
Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?
|
|
Aug 8
|
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
|
|
Jul 30
|
EVAX: Initiating Coverage of Evaxion
|
|
Jun 26
|
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
|
|
Jun 13
|
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
|
|
May 28
|
Evaxion Announces Business Update and First Quarter 2024 Financial Results
|
|
May 24
|
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment
|
|
May 23
|
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
|
|
May 10
|
Evaxion Receives Nasdaq Notification
|
|
May 7
|
Sidoti Events, LLC's Virtual May Micro-Cap Conference
|
|
Apr 17
|
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
|